Literature DB >> 24682238

Peri-procedural povidone-iodine rectal preparation reduces microorganism counts and infectious complications following ultrasound-guided needle biopsy of the prostate.

Justin R Gyorfi1, Christopher Otteni, Kevin Brown, Amar Patel, Kathleen Lehman, Brett E Phillips, Kalyan Dewan, Girish Kirimanjeswara, Jay D Raman.   

Abstract

PURPOSE: The purpose of the study was to evaluate whether a peri-procedural povidone-iodine rectal preparation (PIRP) prior to transrectal ultrasound-guided prostate needle biopsy (TRUS PNB) can reduce microorganism colony counts and infectious complications.
METHODS: Our institutional TRUS PNB database was reviewed to identify infectious post-biopsy complications (defined as fever >38.5 °C with positive culture). The last 570 biopsy patients were divided into those administered only preoperative oral and/or parenteral antibiotics (n = 456; chronologically cohorts A-D) versus men receiving peri-procedural PIRP in conjunction with standard preoperative antibiotics (n = 114; cohort E). Rectal cultures were obtained in the PIRP cohort to quantify changes in microorganism colony counts.
RESULTS: Mean baseline PSA for patients was 11.6 ng/ml, 63 % were undergoing an initial biopsy, and 17 % had documented use of antibiotic therapy within the previous 6 months. A reduction in infectious complications was observed when comparing the conventional antibiotic (cohorts A-D) versus PIRP (cohort E) group (1.8 vs. 0 %), with the largest magnitude of decline occurring in the concurrent contemporary cohorts (cohort D-5.3 % vs. cohort E-0 %, p = 0.03). Rectal cultures obtained in 92 men before and after PIRP administration noted a 97 % reduction in microorganism colonies (2.1 × 10(5) vs. 6.3 × 10(3) CFU/ml, p < 0.001). No adverse reactions to the PIRP were reported by patients 7 days post-biopsy.
CONCLUSIONS: Peri-procedural PIRP decreased microorganism colony counts and effectively reduced infectious complications following TRUS PNB. This safe, cheap, and simple strategy may be a reasonable alternative to systemic or targeted antibiotic therapy to reduce post-biopsy infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682238     DOI: 10.1007/s00345-014-1291-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.

Authors:  James A Karlowsky; Daryl J Hoban; Melanie R Decorby; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Should we change our prophylactic antimicrobial regimen for prostate biopsy?

Authors:  Margaret S Pearle
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

3.  Is urine culture routinely necessary before prostate biopsy?

Authors:  F Bruyère; B F d'Arcier; J-M Boutin; O Haillot
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-04-06       Impact factor: 5.554

4.  Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.

Authors:  Aisha K Taylor; Teresa R Zembower; Robert B Nadler; Marc H Scheetz; John P Cashy; Diana Bowen; Adam B Murphy; Elodi Dielubanza; Anthony J Schaeffer
Journal:  J Urol       Date:  2012-02-16       Impact factor: 7.450

5.  Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate.

Authors:  F M E Wagenlehner; C Wagenlehner; S Schinzel; K G Naber
Journal:  Eur Urol       Date:  2005-01-18       Impact factor: 20.096

6.  Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.

Authors:  Karel Urbánek; Milan Kolár; Jan Strojil; Dagmar Koukalová; Luboslava Cekanová; Petr Hejnar
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-10       Impact factor: 2.890

Review 7.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.

Authors:  B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

8.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

9.  Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon.

Authors:  Zaher K Otrock; Gerard O Oghlakian; Mariana M Salamoun; Maurice Haddad; Abdul Rahman N Bizri
Journal:  Infect Control Hosp Epidemiol       Date:  2004-10       Impact factor: 3.254

10.  Bacterial sepsis after prostate biopsy--a new perspective.

Authors:  Dirk Lange; Christopher Zappavigna; Reza Hamidizadeh; S Larry Goldenberg; Ryan F Paterson; Ben H Chew
Journal:  Urology       Date:  2009-10-07       Impact factor: 2.649

View more
  7 in total

1.  Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection.

Authors:  Jay D Raman; Kathleen K Lehman; Kalyan Dewan; Girish Kirimanjeswara
Journal:  J Vis Exp       Date:  2015-09-21       Impact factor: 1.355

2.  Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.

Authors:  Daniel M Moreira; Gerald L Andriole; J Curtis Nickel; Claus G Roehrborn; Ramiro Castro-Santamaria; Stephen J Freedland
Journal:  World J Urol       Date:  2017-04-10       Impact factor: 4.226

3.  Topical rectal antiseptic at time of prostate biopsy: how a resident patient safety project has evolved into institutional practice.

Authors:  Rosa Park; Justin Gyorfi; Kalyan Dewan; Girish Kirimanjeswara; Joseph Y Clark; Matthew G Kaag; Kathleen Lehman; Jay D Raman
Journal:  Int Urol Nephrol       Date:  2018-07-17       Impact factor: 2.370

4.  Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial.

Authors:  Georg Salomon; Judith Saul; Sandra Prues; Meike Schneider; Lars Budäus; Derya Tilki; Holger Rohde; Axel Haferkamp; Markus Graefen; Katharina Boehm
Journal:  World J Urol       Date:  2018-02-07       Impact factor: 4.226

5.  Does Leaving the Biopsy Needle in Povidone-Iodine Solution Reduce Infective Complications after Biopsy?

Authors:  Erdal Benli; Abdullah Cirakoglu; Ercan Ogreden; Yeliz Cetinkol; Mustafa Kerem Calgin; Ali Ayyildiz; Ahmet Yüce
Journal:  Adv Urol       Date:  2016-12-20

Review 6.  Strategies for prevention of ultrasound-guided prostate biopsy infections.

Authors:  Diane D Lu; Jay D Raman
Journal:  Infect Drug Resist       Date:  2016-07-08       Impact factor: 4.003

7.  Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship.

Authors:  Shayann Ramedani; Joseph Y Clark; John J Knoedler; Susan MacDonald; Matthew G Kaag; Suzanne B Merrill; Jay D Raman
Journal:  Prostate Int       Date:  2021-05-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.